Clinical Trials Arena on MSN
Corxel to advance oral obesity drug to Phase III trials
Corxel’s CX11, an oral GLP-1RA, led to weight loss of up to 11.5% in positive Phase II results.
Morning Overview on MSN
Weight-loss drugs delivered big results but left doctors with big unanswered questions
Semaglutide and tirzepatide have produced some of the largest weight reductions ever recorded in clinical trials, with losses ...
The natural GLP-1 hormone survives in the body for only a few minutes before it is broken down. Drug developers overcome this limitation through advanced molecular engineering techniques.
Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels.
Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist medication approved by the Food and Drug Administration (FDA) to treat type 2 diabetes. While providers may prescribe this drug off label ...
Led by the renowned bariatric surgeon Dr. Amit Taggar, the family-owned practice marks one year of patient-centered, advanced weight loss surgery in Tampa, FL. At TWLI, patients are treated like ...
If you find that you’re not losing weight on Ozempic or other GLP-1 medications, your metabolism, or how quickly your body burns calories, may be the cause. It’s sometimes called the “Ozempic plateau, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results